But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers. Pfizer, in particular, could be ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

Parents in the United States who want to vaccinate their young children against Covid-19 may face a growing set of challenges this fall. The US Food and Drug Administration might not renew ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...

The Pfizer Covid vaccine increased the risk of heart problems for children sixfold in the first week of having the jab but led to fewer cases in the long term, research suggests. British experts who ...